Chrysamine G

Chrysamine G

SCHEMBL7706036

O=C(O)c1cc(/N=N/c2ccc(-c3ccc(/N=N/c4ccc(O)c(C(=O)O)c4)cc3)cc2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
APP P05067 1/20 1.00
THRB P10828 1/20 1.00
RECQL P46063 1/20 1.00
BLM P54132 1/20 1.00
BLVRB P30043 2/20 0.85
PDE4A P27815 1/20 0.85
KDR P35968 1/20 0.85
HTT P42858 1/20 0.85
PHLPP2 Q6ZVD8 4/20 0.69
ALDH1A1 P00352 3/20 0.69
PTGS2 P35354 2/20 0.69
CYP2C9 P11712 2/20 0.69
TSHR P16473 2/20 0.69
PTGS1 P23219 1/20 0.69
HSD17B10 Q99714 1/20 0.69
CYP2D6 P10635 1/20 0.69
CYP2C19 P33261 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chrysamine G SCHEMBL7706038 1.00 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB
Chrysamine G SCHEMBL15818025 0.98 MEN1 (0.96) MEN1KMT2ATDP1APPTHRB
Chrysamine G SCHEMBL15818022 0.98 MEN1 (0.96) MEN1KMT2ATDP1APPTHRB
SCHEMBL7711257 0.95 MEN1 (0.90) MEN1KMT2ATDP1APPTHRB
SCHEMBL7711260 0.95 MEN1 (0.90) MEN1KMT2ATDP1APPTHRB
Olsalazine SCHEMBL25118 0.92 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB
Olsalazine SCHEMBL29861404 0.92 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB
Olsalazine SCHEMBL29385751 0.92 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB
Olsalazine SCHEMBL29378994 0.92 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB
Olsalazine SCHEMBL25119 0.92 MEN1 (1.00) MEN1KMT2ATDP1APPTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4427033-B1 METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA BIOTECH GMBH (DE) 2026-05-20 EP claimed
WO-2025224727-A1 p53 amyloid-binding composition, method, and kit thereof INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) 2025-10-30 WO claimed
EP-4427033-A1 METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA Biotech GmbH (DE) 2024-09-11 EP claimed
US-20240066153-A1 CEST-MRI Methods for Detection of Diseases ALBATANY MOHAMMED ABDELRAHEEM (CA) 2024-02-29 US claimed
EP-4292654-A2 DETECTION OF MISFOLDED PROTEINS Board of Regents of the University of Texas System (US) 2023-12-20 EP claimed
US-20230147467-A1 Novel Contrast Agents and Imaging Methods for Early Detection of Diseases ALGBURI ISHTAR FAISAL (CA) 2023-05-11 US claimed
WO-2023079052-A1 METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA BIOTECH GMBH (DE) 2023-05-11 WO claimed
US-20220313171-A1 Imaging and Treatment Methods for Early Detection of Diseases ALGBURI ISHTAR FAISAL (CA) 2022-10-06 US claimed
US-12636385-B2 Selective ligands for tau aggregates SENTONIX, INC. (US) 2026-05-26 US disclosed
EP-4427033-B1 METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA BIOTECH GMBH (DE) 2026-05-20 EP disclosed
US-20260133206-A1 MISFOLDED PROTEIN DETECTION IN THE EYE LACRISTAT LLC (US) 2026-05-14 US disclosed
EP-4115976-B1 REACTION VESSEL ALOIS DATA GMBH (DE) 2026-04-29 EP disclosed
EP-4724816-A2 METHODS FOR DETECTING THE PRESENCE OF AT LEAST ONE MISFOLDED FORM OF SOD1 IN A BIOLOGICAL SAMPLE Mclaughlin Research Institute for Biomedical Sciences (US) 2026-04-15 EP disclosed
US-12540949-B2 Detection of misfolded alpha synuclein protein BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-02-03 US disclosed
EP-1110945-A2 Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition UNIVERSITY OF PITTSBURGH (US) 2001-06-27 EP disclosed
US-6168776-B1 Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition UNIVERSITY OF PITTSBURGH 2001-01-02 US disclosed
US-6133259-A DIAGNOSIS OF ALZHEIMER'S DISEASE UNIVERSITY OF PITTSBURGH (US) 2000-10-17 US disclosed
US-6114175-A AMYLOID-BINDING COMPOUNDS WHICH ARE NON-AZO DERIVATIVES OF CHRYSAMINE G TO DETERMINE DEGREE OF BRAIN DEPOSITS QUANTITATIVELY CHARACTERIZED BY AMYLOIDOSIS; DOWN'S SYNDROME; PREVENT CELL DEGENERATION; RADIOACTIVE IMAGING UNIVERSITY OF PITTSBURGH (US) 2000-09-05 US disclosed
US-4058607-A DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES AIRWICK INDUSTRIES, INC. (US) 1977-11-15 US disclosed
US-3966900-A INSECTICIDES AIRWICK INDUSTRIES, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540949-B2 Detection of misfolded alpha synuclein protein SNCA, PARK7, NEFM MEN1 4600/4885KMT2A 4703/4885TDP1 452/4885
US-12636385-B2 Selective ligands for tau aggregates MAPT, PSEN2, PSEN1 MEN1 1162/4885KMT2A 4385/4885TDP1 757/4885
US-20260133206-A1 MISFOLDED PROTEIN DETECTION IN THE EYE SNCA, SAAL1, PRNP MEN1 2655/4885KMT2A 4655/4885TDP1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.